Loading...
•
Jun 30, 2023
Cocrystal Pharma Q2 2023 Earnings Report
Reported financial results for Q2 2023 and provided updates on its antiviral drug development programs.
Key Takeaways
Cocrystal Pharma reported a net loss of $4.2 million, or $0.41 per share, for the second quarter of 2023. The company's cash position is sufficient to fund planned operations for the next 12 months.
Advanced novel oral PB2 inhibitor CC-42344 for influenza A, submitting an application for UK MHRA approval to begin a Phase 2a human challenge trial.
Received approval from the Australian regulatory agency to begin a first-in-human trial with novel, broad-spectrum oral protease inhibitor CDI-988 for COVID-19.
Selected CDI-988 as the lead oral norovirus candidate.
Expect to report top-line data of CDI-988 Phase 1 study in 2024.
Forward Guidance
Cocrystal Pharma believes its current cash position is sufficient to fund planned operations for the next 12 months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...